The following represents disclosure information provided by authors of this abstract. The program committee has reviewed all presenting author disclosure reports, identified potential conflicts of interest, and implemented strategies to manage those areas of conflict, where appropriate. All relationships are considered compensated. Relationships are self-held unless otherwise noted. I = Immediate Family Member, Inst = My Institution
 
Open Payments is a public database containing information reported by companies about payments made to US-licensed physicians (Open Payments)
A phase Ib/IIa study of rucaparib (PARP inhibitor) combined with nivolumab in metastatic castrate-resistant prostate cancer and advanced/recurrent endometrial cancer.
 
Raanan Alter
No Relationships to Disclose
 
Gini F. Fleming
Research Funding - Abbvie (Inst); Astex Pharmaceuticals (Inst); Corcept Therapeutics (Inst); Forty Seven (Inst); Genentech (Inst); Iovance Biotherapeutics (Inst); Merck (Inst); Syndax (Inst); Syros Pharmaceuticals (Inst); Tesaro (Inst)
 
Walter Michael Stadler
Consulting or Advisory Role - AstraZeneca; Bayer; Bristol-Myers Squibb; Clovis Oncology; CVS Caremark; Eisai; Merck; Pfizer; Roche/Genentech; Sotio
Research Funding - Abbvie (Inst); AstraZeneca (Inst); Bayer (Inst); Boehringer Ingelheim (Inst); Bristol-Myers Squibb (Inst); Calithera Biosciences (Inst); Clovis Oncology (Inst); Eisai (Inst); Exelixis (Inst); Genentech/Roche (Inst); GlaxoSmithKline (Inst); Janssen (Inst); Johnson & Johnson (Inst); Medivation (Inst); Merck (Inst); Millennium (Inst); Novartis (Inst); Pfizer (Inst); Seagen (I); Tesaro (Inst); X4 Pharma (Inst)
Other Relationship - American Cancer Society; UpToDate
 
Akash Patnaik
Honoraria - Clovis Oncology; Janssen Oncology; Merck; Prime Oncology
Consulting or Advisory Role - Janssen Oncology
Research Funding - Bristol-Myers Squibb (Inst); Clovis Oncology (Inst); Janssen Oncology (Inst); Progenics (Inst)
Travel, Accommodations, Expenses - Bristol-Myers Squibb; Clovis Oncology; Janssen Oncology; Merck; Prime Oncology